Thrombotic thrombocytopenic purpura: Reducing the risk?

Michael Berndt, Robert Andrews

Research output: Contribution to journalLetterOther

6 Citations (Scopus)


von Willebrand factor (vWF) has a key role in initiating platelet aggregation, and thereby thrombus formation, that is dependent on its ability to form appropriately sized multimers. Ultralarge multimers promote the formation of the microvascular thrombi that are hallmarks of the life-threatening condition thrombotic thrombocytopenic purpura (TTP). In this issue of the JCI, Chen et al. show that the drug N-acetylcysteine (NAC) can decrease the size of vWF multimers in vitro and in vivo, resolving thrombi in mice. These data suggest that NAC could potentially be used to treat thrombotic conditions such as TTP.
Original languageEnglish
Pages (from-to)522 - 524
Number of pages3
JournalEuropean Journal of Clinical Investigation
Issue number2
Publication statusPublished - 2011

Cite this